Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer

Journal of Molecular Medicine

Volumn 84, Issue 10, 2006, Pages 833-841

  Burger, Maximilian ^a   Denzinger, Stefan ^a   Hammerschmied, Christine G ^a   Tannapfel, Andrea ^b   Obermann, Ellen C ^a   Wieland, Wolf F ^a   Hartmann, Arndt ^a   Stoehr, Robert ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

EMAST; Mismatch repair; MSI; p53; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; PROTEIN MSH2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; COLORECTAL CANCER; CONSENSUS; CORRELATION ANALYSIS; DINUCLEOTIDE REPEAT; DISEASE COURSE; ELEVATED MICROSATELLITE ALTERATION AT SELECTED TETRANUCLEOTIDE; GENE EXPRESSION; HEALTH CARE ORGANIZATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATION; OVARY TUMOR; PHENOTYPE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKIN CANCER; STAINING; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CARRIER PROTEINS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749172997     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-006-0074-0     Document Type: Article

References (55)

1. Varmus HE (1984) The molecular genetics of cellular oncogenes. Annu Rev Genet 18:553-612
2. Weinberg RA (1991) Tumor-suppressor genes. Science 254:1238-1246
3. Ionov P, Perinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitious somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561
4. Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075-3079
5. Loeb KR, Loeb LA (2000) Significance of multiple mutations in cancer. Carcinogenesis 21:379-385
6. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396:643-649
7. Duval A, Iacopetta B, Ranzani GN, Lothe RA, Thomas G, Hamlin R (1999) Variable mutation frequencies in coding repeats of TCF-4 and other target genes in colon, gastric and endometrial carcinoma showing microsatellite instability. Oncogene 18: 6806-6809
8. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Biags MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257
9. Danaee H, Nelson HH, Karagas MR, Schned AR, Ashok TDS, Hirao T, Perry AE, Kelsey KT (2002) Microsatellite instability at tetranucleotide repeats in skin and bladder cancer. Oncogene 21:4894-4899
10. Catto JWF, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O, Meith M (2003) Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 22:8699-8706
11. Ahrendt SA, Decker PA, Doffek K, Wang B, Xu L, Demeure MJ, Jen J, Sidransky D (2000) Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small lung cancer. Cancer Res 60:2488-2491
12. Singer G, Kallinowski T, Hartmann A, Dietmaier W, Wild PJ, Schraml P, Sauter G, Mihatsch MJ, Moch H (2004) Different types of microsatellite instability in ovarian carcinoma. Int J Cancer 112:643-646
13. Quinn DI, Henshall SM, Sutherland RL (2005) Molecular markers of prostate cancer outcome. Eur J Cancer 41:858-887
14. von Knobloch R, Konrad L, Barth PJ, Brandt H, Wille S, Heidenreich A, Moll R, Hofmann R (2004) Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin Cancer Res 10:1064-1073
15. Chen Y, Wang J, Fraig MM, Henderson K, Bissada NK, Watson DK, Schweinfest CW (2003) Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol 22:1033-1043
16. Valesco A, Hewitt SM, Alber PS, Saboorian MH, Rosenberg H, Martinez C, Sagalowsky AI, McConnell JD, Linehan WM, Leach FS (2002) Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 94:690-699
17. Prtilo A, Leach FS, Markwalder R, Kappeler A, Burkhard FC, Cecchini MG, Studer UE, Thalmann GN (2005) Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol 174:1814-1818
18. Epstein JI, Algaba F, Allsbrook WC, Bastacky S et al (2004) Tumours of the prostate. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) World Health Organization, classification of tumours. Pathology and genetic. Tumours of the urinary system and male genital organs. IARC, Lyon, pp 159-216
19. Sobin LH, Wittekind C (1997) TNM classification of malignant tumours. Wiley-Liss, New York
20. Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, Hammerschmied C, Wieland WF, Knuechel R, Hartmann A (2005) Deletions of chromosomes 9 and 8p in histologically normal urothelium in patients with bladder cancer. Eur Urol 47:58-63
21. Hartmann A, Stoehr R, Wild PJ, Knuechel R (2005) Microdissection for detecting genetic alterations in early and advanced human urinary bladder cancer. Methods Mol Biol 239:79-92
22. Futureal P, Barret JC, Wiesman RW (1991) An alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res 19:6977
23. Schlegel J, Bocker T, Zirngibl H, Hofstaedter F, Ruschoff J (1995) Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening technique. Virchows Arch 426:223
24. Kasper G, Weiser AA, Rump A, Sparbier K, Dahl E, Hartmann A, Wild P, Schwidetzky U, Castanos-Velez E, Lehmann K (2005) Expression levels of putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients. Int J Cancer 117:961-973
25. Catto JWF, Xinarianos G, Burton JL, Meuth M, Hamdy FC (2003) Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 105:484-490
26. Dietmeier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J (1997) Diagnostic microsatellite instability. Definition and correlation with mismatch repair protein expression. Cancer Res 57:4749-4756
27. Samowitz W, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, Robertson MA, Nichols MF, Gruenthal KM, Lynch BJ, Leppert MF, Slattery ML (2001) Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 158:1517-1524
28. Xu LH, Chow J, Bonacum J, Eisenberger C, Ahrendt SA, Spafford M, Wu L, Lee SM, Piantadosi S, Tockman MS, Sidransky D, Jen J (2001) Microsatellite instability at AAAG repeat sequence in respiratory tract cancers. Int J Cancer 91:200-204
29. Ahman AK, Jonsson BA, Damber JE, Bergh A, Groenberg H (2001) Low frequency of microsatellite instability in hereditary prostate cancer. BJU Int 87:334-338
30. Gao X, Wu N, Grignon D, Zacharek A, Liu H, Salkowski A, Li G, Sakr W, Sarkar F, Porter AT, Chen YQ, Honn KV (1994) High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 9:2999-3003
31. Rohrbach H, Haas CJ, Baretton GB, Hirschmann A, Diebold J, Behrendt RP, Loehrs U (1999) Microsatellite instability and loss of heterozygosity in prostatic carcinomas: comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. Prostate 40:20-27
32. Lothe RA (1997) Microsatellite instability in human solid tumors. Mol Med Today 3:61-68
33. Kloor M, Schwitalle Y, von Knebel-Doeberitz M, Wentzensen N (2006) Tetranucleotide repeats in coding regions: no evidence for involvement in EMAST carcinogenesis. J Mol Med 84(4):329-333 DOI 10.1007/s00109-005-0012-6
34. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB (1996) An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814-3822
35. Fan K, Dao DD, Schutz M, Fink LM (1994) Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma. Diagn Mol Pathol 3:265-270
36. Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Diener PA, Bannwart F, Schafer R, Schwarte-Waldhoff I (1994) P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res 14:2785-2790
37. Macera MJ, Godec CJ, Sharma N, Verma RS (1998) Loss of heterozygosity of the TP53 tumor suppressor gene and detection of point mutations by the nonisotopic RNAse cleavage assay in prostate cancer. Cancer Genet Cytogenet 108:42-47
38. Wu YQ, Chen H, Rubin MA, Wojno KJ, Cooney KA (2001) Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. Cancer Res 61:8651-8653
39. Huges C, Murphy A, Martin C, Sheils O, O'Leary J (2005) Molecular pathology of prostate cancer. J Clin Pathol 58:673-684
40. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O (2005) Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66:332-337
41. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M (2005) Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25:3132-3133
42. Moul JW, Merseburger AS, Srivastava S (2002) Molecular markers in prostate cancer: the role in preoperative staging. Clin Prostate Cancer 1:42-50
43. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson G (2004) Hypermethylation of CpG islands in primary and metastatic prostate cancer. Cancer Res 64:1975-1986
44. Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q (2001) Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate 47:269-275
45. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2005) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 23:1-8
46. Leach FS, Hsieh JT, Molberg K, Saboorian MH, McConnell JD, Sagalowsky AI (2000) Expression of human mismatch repair gene hMSH2: a potential marker for urothelial malignancy. Cancer 88:2333-2341
47. Rass K, Gutwein P, Welter C, Meineke V, Tilgen W, Reichrath J (2001) DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines. Histochem J 33:459-467
48. Castrilli G, Fabiano A, La Torre G, Marigo L, Piantelli C, Perfetti G, Ranelletti FO, Piantelli M (2002) Expression of hMSH2 and hMLH1 proteins of the human DNA mismatch repair system in salivary gland tumors. J Oral Pathol Med 31:234-238
49. Srivastava T, Chattopadhyay P, Mahapatra AK, Sarkar C, Sinha S (2004) Increased hMSH2 protein expression in glioblastoma multiforme. J Neurooncol 66:51-57
50. Giarnieri E, Consorti F, Lorenzotti A, Luzzatto L, Soda G, Bosco D, Vecchione A, Midiri G (2000) Altered expression of hMSH2 in sporadic colorectal cancer, surrounding mucosa and at distant colonic mucosa. Anticancer Res 20:3829-3831
51. Marra G, Chang CL, Laghi LA, Chauhan DP, Young D, Boland CR (1996) Expression of MutS homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene 13:2189-2196
52. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T (2003) Expression of ERalpha and ERbeta in prostate cancer. Prostate 55:180-186
53. Bonkhoff H, Motherby H, Fixemer T (2003) New insights into the role of estrogens and their receptors in prostate cancer. Urologe A 12:1594-1601
54. Wada-Hiraike O, Yano T, Nei T, Matsumoto Y, Nagasaka K, Takizawa S, Oishi H, Arimoto T, Nakagawa S, Yasugi T, Kato S, Taketani Y (2005) The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br J Cancer 92:2286-2291
55. Nanni S, Narducci M, Delle Pietra L, Moretti F, Grasselli A, De Carli P, Sacchi A, Pontecorvi A, Farsetti A (2002) Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest 110:219-227